




RealRate

PHARMACEUTICAL 2013

Alaunos Therapeutics Inc
Rank 185 of 218

ALAUNOSTM
THERAPEUTICS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Alaunos Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alaunos Therapeutics Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 16% points. The greatest weakness of Alaunos Therapeutics Inc is the variable Net Income, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 68%, being 152% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	80,276
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,864
Liabilities, Non-Current	12,962
Other Assets	1,134
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,133
Other Net Income	15,472
Other Revenues	1,467
Property and Equipment	1,994
Research and Development	212,345
Selling, General and Administrative Expense	88,318

Output Variable	Value in 1000 USD
Assets	83,404
Liabilities	34,959
Expenses	300,663
Revenues	1,467
Stockholders Equity	48,445
Net Income	-283,724
Comprehensive Net Income	-283,724
BaseVar	217,982
ECR before LimitedLiability	-301%
Economic Capital Ratio	68%